Beactica Therapeutics, the Swedish drug discovery company, today announced the appointment of a Head of Preclinical Development, two new members of the Board, and a clinical advisor. The appointments are made to strengthen the organisation as the company sharpens its strategic focus on drug discovery and development.
Vendela Parrow, PhD is appointed to Head of Preclinical Development. She brings with her an extensive experience in preclinical and clinical development from key positions at Akinion Pharmaceuticals, Axelar and Pharmacia Biovitrum. Vendela was a Co-founder,